2. UroToday Home
  3. Video Lectures

mHSPC Videos

Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer in the US - Umang Swami
April 1, 2025
Details
PSA Nadir Predicts Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Patients - Hannah McManus
March 26, 2025
Details
PSA Responses with Darolutamide Plus ADT in the ARANOTE Trial - Fred Saad
March 24, 2025
Details
ARASENS Trial Analysis Investigates Impact of Initial PSA Values on Treatment Response in mHSPC - Alicia Morgans
March 23, 2025
Details
LIBERTAS Clinical Trial Explores Treatment Optimization in mHSPC - Arun Azad
March 20, 2025
Details
Investigating PARP Expression as Biomarker for Targeted Therapy in Prostate Cancer - Emmanuel Antonarakis
March 20, 2025
Details
Examining Post-Prostatectomy Metastasis Patterns in Hormone-Sensitive Prostate Cancer - Nicolas Sayegh
March 19, 2025
Details
Comparing ARPI Options Across Disease Volume and Metastatic Timing in mHSPC - Syed Arsalan Ahmed Naqvi & Irbaz Riaz
March 19, 2025
Details
PERSIAN Trial Explores SBRT Benefits in Oligometastatic Hormone-Sensitive Prostate Cancer - Giulio Francolini
March 18, 2025
Details
Cardiovascular Management in Advanced Prostate Cancer - Zeynep Irem Ozay
March 12, 2025
Details
Tumor Suppressor Gene Status Refines Prognosis and Treatment Selection in Metastatic Prostate Cancer - Martino Pedrani
March 8, 2025
Details
IMPLEMENT Study Reveals Barriers to Treatment Intensification in Metastatic Prostate Cancer - Stacy Loeb
March 6, 2025
Details
ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh
February 27, 2025
Details
Patient-Level Data Confirms ARPI Value in mHSPC Treatment in Meta-Analysis - David Fisher
February 27, 2025
Details
ARANOTE Trial Explores Darolutamide’s Role in High and Low-Volume Metastatic Prostate Cancer - Fred Saad
February 24, 2025
Details
ADT Remodels the Tumor Microenvironment from Immunologically Cold to Hot - Matthew Dallos
February 10, 2025
Details
Physician Decision Making & Combination Therapies in Metastatic Prostate Cancer - Neeraj Agarwal
January 28, 2025
Details
VA Study Examines Use of Combination Therapies for mHSPC and Outcomes in Patients - Martin Schoen & Bruce Montgomery
December 13, 2024
Details
Introduction to mHSPC – What Are Relevant Prognostic/Predictive Factors for the Management of Patients? "Presentation" - Matthew Smith
November 15, 2024
Details
Synchronous Low-Volume mHSPC – in Which Patients Do You Recommend Combination Systemic Therapy plus Local Treatment of the Primary and in Which Patients Is ADT Alone plus RT Enough? "Presentation" - Robert Jones
November 15, 2024
Details
In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Oliver Sartor
November 15, 2024
Details
Which Patients with mHSPC Should Get Triplet Systemic Therapy: ADT plus Docetaxel plus ARPI? "Presentation" - Nicholas James
November 15, 2024
Details
Should the Primary be Treated in Synchronous High-Volume mHSPC? "Presentation" - Sandy Srinivas
November 15, 2024
Details
In Which Patients with Metachronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Thomas Zilli
November 15, 2024
Details
Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice? "Presentation" - Michael Morris
November 15, 2024
Details
Optimal Treatment Sequencing in Metastatic Prostate Cancer "Discussion"
November 15, 2024
Details
Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? "Presentation" - Bertrand Tombal
November 15, 2024
Details
Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better? "Presentation" - Mary-Ellen Taplin
November 15, 2024
Details
How to Manage Patients with Low-Volume on Conventional and High-Volume on NGI "Presentation" - Dana Rathkopf
November 15, 2024
Details
Management of Patients with mHSPC and Early Progression on Combination Therapy "Presentation" - Christopher Sweeney
November 15, 2024
Details
Management of Frail Patients with mHSPC "Presentation" - Maria De Santis
November 15, 2024
Details
Future Changes in the Setting of mHSPC "Presentation" - Gerhardt Attard
November 15, 2024
Details
Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke
November 15, 2024
Details
Balancing Risks and Benefits of ADT in Prostate Cancer Treatment "Discussion"
November 15, 2024
Details
Ideal Sequence After ADT Alone or ADT plus ARPI for mHSPC "Presentation" - Ian Davis
November 15, 2024
Details
Ideal Sequence After ADT plus ARPI plus Docetaxel for mHSPC "Presentation" - Karim Fizazi
November 15, 2024
Details
MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter
November 5, 2024
Details
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
November 5, 2024
Details
Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen
October 30, 2024
Details
UpFrontPSMA Trial Results: Lutetium-177 PSMA-617 in Hormone-Sensitive Prostate Cancer, Journal Club - Phillip Koo & Zachary Klaassen
October 15, 2024
Details
STAMPEDE2 Trial Explores Combination Niraparib and Abiraterone in mHSPC - Sarah Howlett & Mahaz Kayani
October 15, 2024
Details
ARANOTE Trial Implications for Metastatic Prostate Cancer Management, Journal Club - Rashid Sayyid & Zachary Klaassen
October 12, 2024
Details
First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract
October 9, 2024
Details
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad
October 7, 2024
Details
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard
October 1, 2024
Details
Accelerated 177Lu-PSMA-617 Protocol Tested in STAMPEDE2 - Minal Padden-Modi & Nicholas James
September 27, 2024
Details
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad
September 26, 2024
Details
STAMPEDE2 SABR Trial for Oligometastatic Prostate Cancer Treatment - Hoda Abdel-Aty
September 24, 2024
Details
UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad
September 23, 2024
Details
Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros
September 20, 2024
Details
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
September 19, 2024
Details
ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo
September 18, 2024
Details
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad
September 16, 2024
Details
PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel
September 16, 2024
Details
2024 NCCN Prostate Cancer Guidelines: Updates in M1 CSPC Treatment - Rashid Sayyid & Zachary Klaassen
September 6, 2024
Details
Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen
August 23, 2024
Details
RADIOSA Trial: SBRT vs SBRT+ADT for Oligorecurrent Prostate Cancer - Giulia Marvaso
August 21, 2024
Details
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
June 18, 2024
Details
NCCN 2024 Prostate Cancer Guidelines Update: Relugolix Gains Prominence in Treating Metastatic Castration-Sensitive Prostate Cancer - Rashid Sayyid & Zachary Klaassen
June 15, 2024
Details
Enzalutamide Plus 5-Alpha Reductase Inhibitors for Castrate-Sensitive Prostate Cancer: A Phase 2 Trial - Deepak Kilari
June 13, 2024
Details
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
June 12, 2024
Details
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
June 12, 2024
Details
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
May 28, 2024
Details
Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas
May 28, 2024
Details
Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
May 24, 2024
Details
Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis
May 24, 2024
Details
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
May 23, 2024
Details
Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris
May 23, 2024
Details
The EvoPAR-Prostate 01 Trial: Novel PARP Inhibitor Saruparib in mHSPC - Neeraj Agarwal
May 22, 2024
Details
Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal
April 23, 2024
Details
Local Therapy in mHSPC: Who Does Really Benefit? - Alberto Bossi
April 23, 2024
Details
Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses
April 15, 2024
Details
The Role of Urologists in Managing De Novo Metastatic Prostate Cancer - Benjamin Lowentritt
April 15, 2024
Details
Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer
April 15, 2024
Details
Best Practices for Successfully Implementing Triplet Therapy in mHSPC - Christopher Pieczonka
April 12, 2024
Details
Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi
April 12, 2024
Details
Urology-Oncology Collaboration: Keys to Optimal Care in Metastatic Prostate Cancer - Damian Sorce & Manojkumar Bupathi
April 5, 2024
Details
Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia
March 20, 2024
Details
Optimizing mHSPC Care and Collaboration for Triplet Therapy - Jason Hafron & Elisabeth Heath
March 13, 2024
Details
ARASENS Subgroup Analysis on Triplet Therapy Improves Outcomes for Black Patients with mHSPC, Journal Club - Rashid Sayyid & Zachary Klaassen
March 11, 2024
Details
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans
March 1, 2024
Details
Adopting a Multidisciplinary Approach to Optimize Treatment Decisions for Patients with Metastatic Prostate Cancer - Michael Williams & Mark Fleming
March 1, 2024
Details
LIBERTAS Trial Tests Less Treatment, Better Quality of Life in Responding mHSPC Patients - Arun Azad
February 29, 2024
Details
Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell
February 22, 2024
Details
Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt
February 20, 2024
Details
Collaborating on Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Daniel Saltzstein
February 5, 2024
Details
Building an Integrated, Multidisciplinary Team to Optimize Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Chandler Park & Ryan Malone
February 5, 2024
Details
Communication for Optimal Care in Patients Selected for Triplet Therapy Between Urology and Community Oncology - Vahan Kassabian & Sreekanth Reddy
January 29, 2024
Details
Sharing Care within Private Clinics for Patients with Newly Diagnosed mHSPC - David Morris & Benjamin Garmezy
January 29, 2024
Details
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
December 15, 2023
Details
Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyond the Abstract
December 12, 2023
Details
Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu
December 11, 2023
Details
ARASENS Phase 3 Clinical Trial Regimen Demonstrates Significant Survival Benefit for Chinese Patients - Yong YANG
December 11, 2023
Details
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic
November 29, 2023
Details
Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard
November 17, 2023
Details
Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - Fred Saad
June 27, 2023
Details
Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal
June 14, 2023
Details
The Combination of Enzalutamide Plus Talazoparib for Patients With Castration-Sensitive Metastatic Prostate Cancer With HRR Gene Alterations (TALAPRO-3) - Neeraj Agarwal
March 4, 2023
Details
mHSPC Network Meta-Analysis on the Use of Intensified Treatments - Fred Saad
February 3, 2023
Details
Treatment Intensification in Metastatic Castrate-Sensitive Prostate Cancer - Zachary Klaassen
February 2, 2023
Details
Considerations for Integrating Triplet Therapy Into Clinical Practice - Evan Yu
January 31, 2023
Details
Meta-Analysis Sheds Light on Optimal Treatment Strategies for Metastatic Hormone-Sensitive Prostate Cancer - Benjamin Maughan
January 26, 2023
Details
Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg
January 23, 2023
Details
Progress in Treating Metastatic Castration-Sensitive Prostate Cancer - Karim Fizazi
January 17, 2023
Details
mCSPC Couplet vs Triplet Therapy LUGPA 2022 Presentation - Alicia Morgans
December 15, 2022
Details
Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay
December 5, 2022
Details
The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz
November 16, 2022
Details
8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam
November 11, 2022
Details
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore
October 17, 2022
Details
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
October 16, 2022
Details
(AFT19) PRESTO Study Prolonging Biochemical Progression-Free Survival in Biochemically Relapsed Prostate Cancer with Intensification of ADT - Charles Ryan
October 12, 2022
Details
Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal
October 12, 2022
Details
From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi
September 27, 2022
Details
Treatment of Vulnerable/Frail Patients with mHSPC APCCC 2022 Presentation - Alicia Morgans
September 21, 2022
Details
Optimal Treatment for mHSPC from a Health Economics Standpoint APCCC 2022 Presentation - Caroline Clarke
September 21, 2022
Details
Can Biology Help Inform Treatment Decisions In the Management of mHSPC? APCCC 2022 Presentation - Gert Attard
September 11, 2022
Details
Advancing Treatment for Metastatic Hormone-Sensitive Prostate Cancer: Insights from ARASENS Trial - Jan Philipp Radtke
August 31, 2022
Details
Treatment De-escalation Strategies in mHSPC APCCC 2022 Presentation - Bertrand Tombal
August 23, 2022
Details
Treatment Intensification Strategies in mHSPC: Triplets and More APCCC 2022 Presentation - Christopher Sweeney
August 23, 2022
Details
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Treat like Low-Volume APCCC 2022 Presentation - Karim Fizazi
August 22, 2022
Details
When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - How Frequent Is This Situation? APCCC 2022 Presentation - Michael Hofman
August 22, 2022
Details
The Uptake of New Treatment Options for mHSPC in Real Life -- Education, Access, Use, and Diversity APCCC 2022 Presentation - Andrew Armstrong
August 22, 2022
Details
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore
August 8, 2022
Details
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal
August 8, 2022
Details
Darolutamide Approved for Patients with mHSPC - Charles Ryan
August 5, 2022
Details
De-escalation Treatment Strategies in Metastatic Hormone-Sensitive Prostate Cancer - Bertrand Tombal
June 24, 2022
Details
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Karim Fizazi
June 19, 2022
Details
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
June 8, 2022
Details
Real-World Treatment Trends in Metastatic Castration-Sensitive Prostate Cancer - Pedro Barata
March 25, 2022
Details
Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore
March 23, 2022
Details
ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen
March 21, 2022
Details
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
February 24, 2022
Details
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
December 2, 2021
Details
The Efficacy of Enzalutamide + ADT vs Placebo + ADT in Patients Who Received Prior Antiandrogen Therapy in the ARCHES Study – Neal Shore
September 27, 2021
Details
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
September 19, 2021
Details
Radiographic Progression Free Survival in Metastatic Hormone Sensitive Prostate Cancer, The ARCHES Study - Daniel Petrylak
July 18, 2021
Details
The Upfront PSMA Study: Shifting Paradigms in Metastatic Hormone-Sensitive Disease - Declan Murphy & Arun Azad
July 1, 2021
Details
Intensification of Hormonal Therapy for Men With Metachronous Metastatic Hormone-Sensitive Disease – Chris Sweeney
June 21, 2021
Details
Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal
May 13, 2021
Details
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
April 30, 2021
Details
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer - Matthew Deek & Phuoc Tran
February 14, 2021
Details
Standard of Care in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer - Michael Morris & Christopher Sweeney
September 13, 2020
Details
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
June 26, 2020
Details
Quality of Life in the Treatment of mHSPC: The STAMPEDE Trial - Hannah Rush
March 3, 2020
Details
Categorizing Patients with Hormone-Sensitive Prostate Cancer - Christopher Sweeney
February 2, 2020
Details
Systemic Therapies in High Volume & Low Volume Disease in the Treatment of Metastatic Hormone Sensitive Prostate Cancer from the STAMPEDE Trial- Nick James
January 1, 2020
Details
The Biology of Prostate Cancer - Kenneth Pienta
November 26, 2019
Details
Prolonging Time to Metastatic Disease, The SPARTAN Study - Matthew Smith
October 29, 2019
Details
Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer - Neeraj Agarwal
October 22, 2019
Details
Treating the Primary in High vs Low Volume Hormone Sensitive Disease - Interview Noel Clarke
October 4, 2019
Details
First - Line mCRPC After ADT + Docetaxel or AR Pathway Inhibitor Presentation - Mary-Ellen Taplin
September 24, 2019
Details
Optimal Glucocorticoid Regimen with Abiraterone Acetate Presentation - Gert Attard
September 16, 2019
Details
Follow Up of ADT Alone vs. ADT "Plus" Presentation - William Oh
September 10, 2019
Details
Addition of AR Pathway Inhibitors vs. Docetaxel: Statisticians' Perspective Presentation - Matthew R Sydes
September 10, 2019
Details
The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin
August 19, 2019
Details
TITAN, TALAPRO-2 And Ongoing Clinical Trials for Prostate Cancer - Neeraj Agarwal
August 18, 2019
Details
Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris
June 22, 2019
Details
Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin
June 5, 2019
Details
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
May 26, 2019
Details
Contemporary Management of Hormone Sensitive Prostate Cancer - Alicia Morgans
April 9, 2019
Details
Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans
June 16, 2019
Details
The Role of the Nurse Practitioner in the Treatment of mHSPC - Leanne Schimke
March 26, 2019
Details
Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans
January 31, 2019
Details
STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen
December 5, 2018
Details
A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney
November 29, 2018
Details
Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer - Robert Hamilton
March 5, 2018
Details